DAB2IP and cancer: In this perspective, powerful insights may come from genomic and transcriptomic analysis of publicly available cancer datasets, such as The Cancer Genome Atlas (TCGA), that could reveal pathways or biological processes preferentially activated in DAB2IP-deficient cancers, possibly uncovering novel targetable mechanisms to induce synthetic lethality in these tumors.